ScholarLens Back to search
2000•Unpublished venueRequires access

Extrapyramidal side effects of risperidone

Pla Jinan

Open publisher page 6 citations

Abstract

Objective:To detect the prevalence of extrapyramidal symptoms (EPS) of risperidone in the treatment of first episodic schizophrenia. Method:Forty six schizophrenic patients,who were first episodic and never administered neuroleptic agents,were assessed with EPS by the extrapyramidal symptom rating scale (ESRS) and evaluated with clinical symptoms by the positive and negative symptom scale (PANSS) before and after treatment. Results:Six patients (13 0%) with significant EPS before treatment didn't recur of EPS;13 patients (28 3%) had dyskinesia or Parkinsonism with risperidone 4~6mg/d,with the reduction of risperidone dosage,these symptoms were lessened or disappeared;other patients with risperidone≤3mg/d had no EPS. Conclusion:The results may play an important role in the early and long term treatment of schizophrenia.

About this research paper

What this paper is about

Objective:To detect the prevalence of extrapyramidal symptoms (EPS) of risperidone in the treatment of first episodic schizophrenia. Method:Forty six schizophrenic patients,who were first episodic and never administered neuroleptic agents,were assessed with EPS by the extrapyramidal symptom rating scale (ESRS) and evaluated with clinical symptoms by the positive and negative symptom scale (PANSS) before and after treatment. Results:Six patients (13 0%) with significant EPS before treatment didn't recur of EPS;13 patients (28 3%) had dyskinesia or Parkinsonism with risperidone 4~6mg/d,with the reduction of risperidone dosage,these symptoms were lessened or disappeared;other patients with risperidone≤3mg/d had no EPS. Conclusion:The results may play an important role in the early and long term treatment of schizophrenia.

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To detect the prevalence of extrapyramidal symptoms (EPS) of risperidone in the treatment of first episodic schizophrenia. Method:Forty six schizophrenic patients,who were first episodic and never administered neuroleptic agents,were assessed with EPS by the extrapyramidal symptom rating scale (ESRS) and evaluated with clinical symptoms by the positive and negative symptom scale (PANSS) before and after treatment. Results:Six patients (13 0%) with significant EPS before treatment didn't recur of EPS;13 patients (28 3%) had dyskinesia or Parkinsonism with risperidone 4~6mg/d,with the reduction of risperidone dosage,these symptoms were lessened or disappeared;other patients with risperidone≤3mg/d had no EPS. Conclusion:The results may play an important role in the early and long term treatment of schizophrenia.

Key concepts: Risperidone, Extrapyramidal symptoms, Parkinsonism, Schizophrenia (object-oriented programming), Dyskinesia, Psychology, Negative symptom, Positive and Negative Syndrome Scale

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Extrapyramidal side effects of risperidone — Research Paper | ScholarLens